PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Vapreotide

Vapreotide (RC-160) is a stable somatostatin analogue with moderate-to-high affinity for somatostatin receptor subtypes 2, 3 and 5.

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

    • established
      Claim: Randomized trial of early vapreotide in variceal bleeding standing
    • resolved

    Early administration of vapreotide for variceal bleeding in patients with cirrhosis.

    Calès P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-Talbodec N, Bronowicki JP, Ribard D, Botta-Fridlund D, Hillon P, Besseghir K, Lebrec D, French Club for the Study of Portal Hypertension

    pmid 11136956

    • preclinical
      Claim: RC-160 receptor subtype affinities and antiproliferative signalling standing
    • resolved

    Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.

    Buscail L, Estève JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C

    pmid 7878022

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.